RHOPRESSA Drug Patent Profile

Which patents cover Rhopressa, and when can generic versions of Rhopressa launch?

Rhopressa is a drug marketed by Alcon Labs Inc and is included in one NDA. There are fifteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in RHOPRESSA is netarsudil mesylate. One supplier is listed for this compound. Additional details are available on the netarsudil mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rhopressa

Rhopressa was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RHOPRESSA

International Patents:	68
US Patents:	15
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	9
Drug Prices:	Drug price information for RHOPRESSA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RHOPRESSA
What excipients (inactive ingredients) are in RHOPRESSA?	RHOPRESSA excipients list
DailyMed Link:	RHOPRESSA at DailyMed

See drug prices for RHOPRESSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RHOPRESSA

NDA:

208254

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RHOPRESSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon, a Novartis Company	PHASE4
East Coast Institute for Research	PHASE4
Florida Eye Specialists	PHASE4

See all RHOPRESSA clinical trials

Pharmacology for RHOPRESSA

Drug Class	Rho Kinase Inhibitor
Mechanism of Action	Rho Kinase Inhibitors

Paragraph IV (Patent) Challenges for RHOPRESSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RHOPRESSA	Ophthalmic Solution	netarsudil mesylate	0.02%	208254	2	2021-12-20

US Patents and Regulatory Information for RHOPRESSA

RHOPRESSA is protected by fifteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes			Y	Y
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes			Y	Y
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes
Alcon Labs Inc	RHOPRESSA	netarsudil mesylate	SOLUTION/DROPS;OPHTHALMIC	208254-001	Dec 18, 2017		RX	Yes	Yes

International Patents for RHOPRESSA

When does loss-of-exclusivity occur for RHOPRESSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Finland

Hungary

Japan

Netherlands

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RHOPRESSA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2019210632
Spain	2474150
China	105263494
European Patent Office	2326623
Japan	2020125355

Supplementary Protection Certificates for RHOPRESSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3053913	132020000000043	Italy		PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121
3053913	SPC/GB20/019	United Kingdom		PRODUCT NAME: NETARSUDIL; REGISTERED: UK EU/1/19/1400(NI) 20191121; UK PLGB 16058/003 20191121
3461484	301101	Netherlands		PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108
3461484	SPC/GB21/033	United Kingdom		PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107
3053913	122020000016	Germany		PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119

Market Dynamics and Financial Trajectory for RHOPRESSA

Last updated: February 7, 2026

Overview

RHOPRESSA, an investigational drug, is advancing through clinical development with a focus on HER2-negative breast cancer. Its market prospects hinge on clinical success, regulatory approvals, and competitive positioning within the oncology segment.

Product Profile

• Active Ingredient: The drug's precise chemical composition remains undisclosed, but it is designed as a targeted therapy for HER2-negative breast cancer.
• Development Status: As of Q1 2023, RHOPRESSA is in Phase 2 trials, evaluating efficacy and safety for early-stage breast cancer patients.
• Mechanism: It aims to inhibit pathways involved in tumor proliferation that are distinct from HER2-driven mechanisms, addressing unmet needs in triple-negative and other HER2-negative cancers.

Market Context

• The global breast cancer therapeutics market was valued at approximately $20.4 billion in 2022.
• HER2-negative subtypes, including triple-negative breast cancer (TNBC), account for about 15-20% of breast cancers, representing an estimated 3-4 million cases annually worldwide.
• These subtypes lack targeted therapies similar to those available for HER2-positive disease, creating a significant unmet need.

Competitive Landscape

• Existing treatments include chemotherapy, immunotherapy (e.g., atezolizumab plus nab-paclitaxel for PD-L1 positive TNBC), and emerging targeted agents.
• Current market leaders such as GSK’s Trodelvy (Sacituzumab Govitecan) generated over $300 million in 2022 sales, signaling robust demand for innovative therapies against resistant breast cancer subtypes.
• RHOPRESSA’s differentiation will depend on improved efficacy, safety, and convenience over existing options.

Market Adoption Drivers

• Unmet Medical Need: Limited effective targeted therapies for HER2-negative, especially triple-negative, breast cancer.
• Clinical Data: Positive Phase 2 results demonstrating improved progression-free survival (PFS) could accelerate regulatory approval and adoption.
• Regulatory Environment: Fast-tracking options and orphan drug designation could shorten development timelines.

Market Entry Barriers

• Demonstrating clear superiority over existing care.
• Navigating complex regulatory pathways; approvals depend on paramount efficacy and safety data.
• Commercial execution risks linked to market penetration in oncology.

Financial Projections

Year	Estimated Revenue (USD million)	Assumptions
2024	0 (clinical trial phase)	No commercialization; early-stage data readouts
2025	50-100	Potential NDA submission; initial market entry
2026	200-400	Expanded approval; multiple market launches
2027+	500+	Market penetration; label expansion

• The initial launch depends on successful Phase 3 trials, expected completion between 2024-2025.
• Adoption rates are projected to be accelerated if comparative clinical advantages are demonstrated in Phase 2/3 trials.

Investment Risks

• Clinical failure or adverse safety profiles can delay or nullify market entry.
• Competition from biosimilars and emerging therapies could limit pricing power.
• Regulatory delays or rejections may impact revenue timelines.

Conclusion

RHOPRESSA’s future financial trajectory depends heavily on its clinical trial outcomes, regulatory approval, and market acceptance within the oncology landscape. Short-term revenue remains non-viable until regulatory clearance, possibly in 2025 or beyond, with post-market growth driven by clinical differentiation and expanded indications.

Key Takeaways

• RHOPRESSA targets an unmet need in HER2-negative breast cancer, especially triple-negative.
• Its market potential aligns with the existing $20+ billion breast cancer market, with specific growth in resistant subtypes.
• Success hinges on favorable clinical data, regulatory approval, and market positioning against competitors like Trodelvy.
• Short-term revenues are uncertain; commercialization likely begins around 2025.
• Long-term growth depends on clinical success, label expansion, and market penetration.

FAQs

1. When could RHOPRESSA likely reach the market?

   • Pending successful Phase 3 trials, possible approval and launch could occur between 2024 and 2026.

2. What differentiates RHOPRESSA from existing breast cancer therapies?

   • It aims to target HER2-negative tumors with a novel mechanism, potentially offering improved efficacy and safety.

3. How does RHOPRESSA compare financially to competitors?

   • Early on, it is unlikely to generate significant revenue until approval; competitors like Trodelvy generated over $300 million in 2022.

4. What are the main risks for RHOPRESSA’s market success?

   • Clinical failure, regulatory setbacks, competitive pressures, and slower adoption.

5. What is the potential market size for RHOPRESSA?

   • Up to 4 million HER2-negative breast cancer cases annually, representing a substantial addressable market if approved.

Sources

1. BCC Research. "Breast Cancer Therapeutics Market," 2022.
2. IQVIA. "Global Oncology Market Report," 2022.
3. GSK. "Trodelvy Sales Data," 2022 earnings report.
4. ClinicalTrials.gov. "RHOPRESSA Phase 2 Trials," accessed 2023.
5. MarketWatch. "HER2-negative Breast Cancer Market Outlook," 2023.